Cobroxin wins 2009 ECRM Health Care Best Product Award
DELRAY BEACH, Fla. Winner of the 2009 ECRM Health Care Best Product Award sponsored by Drug Store News, Xenacare showcased its homeopathic pain-relief remedy Cobroxin.
Available in two delivery forms — a 1 oz. orange-flavored oral spray and 2 oz. topical gel — Xenacare is targeting women over the age of 45 in its initial rollout of Cobroxin. The product will be backed by an $8 million consumer advertising campaign through 2010, the company reported, and will retail for a suggested $18.99 (oral spray) and $19.95 (topical gel).
Xenacare classifies Cobroxin as a category two pain killer, offering pain relief on par with several prescription analgesics without the associated side effects or potential for addiction.
Stiefel zaps acne segment with ‘leave-on’ treatment
DULUTH, Ga. Stiefel Labs, a GlaxoSmithKline company, launched one of the first “leave-on” treatments for acne care, PanOxyl, as a line extension to the company’s acne-care bar and wash.
The formulation is not greasy as compared with spot treatments, and blends into the skin upon application. The new formulation delivers 10% Benzoyl Peroxide in a foam delivery.
In addition to consumer ad support, Stiefel will be fielding its 200-strong dedicated representatives to detail dermatologists.
Stiefel also introduced its Sensitive Sarna eczema itch relief kit, an all-in-one kit that includes a cleanse, itch relief and moisturizer.
New directors elected to NACDS Foundation board
ALEXANDRIA, Va. The National Association of Chain Drug Stores has elected three new directors to the board of the NACDS Foundation.
Jim VanLieshout, VP retail sales with Apotex; Alice Swearingen, VP channel development sales for GlaxoSmithKline; and Chris Dimos, president of pharmacy operations for Supervalu, will fill vacancies on the board, which consists of 22 members.
“We are pleased to welcome the three new members to the NACDS Foundation board of directors,” said Edith Rosato, president of the NACDS Foundation.
“They will continue the strong representation on the board of chains and suppliers alike. We value their expertise, dedication and commitment to the industry, and we look forward to working together for the good of the public and the patients served by community pharmacy.”